What is GBS Inc. (GBS)?

GBS Inc. (GBS) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of GBS?

The current price of GBS is $0.47. Prices are updated in real time on Stocks360.

What is GBS's price-to-earnings (PE) ratio?

GBS's trailing twelve-month PE ratio is -0.06, based on current price and earnings per share data available on Stocks360.

What is GBS's market capitalization?

GBS's market capitalization is $433,577.00, placing it in the small-cap tier.

GBS Inc. (GBS)

Stock analysis · NASDAQ · Healthcare · Medical - Devices

$0.47

Market Cap

$433.58K

PE (TTM)

-0.06

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.00

Day Range

$0.45 – $0.49

52-wk Range

$0.36 – $2.89

Avg Volume

N/A

Volume

9.03K

GBS Inc. (GBS) is a publicly traded company in the Healthcare sector. Latest price: $0.47. Market cap $433.58K. Trailing PE -0.06. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 31, 2022

EPS $-0.14 vs est. $-0.18

Beat by $0.04

Proprietary Signals

Signal snapshot temporarily unavailable.

About GBS Inc.

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.06×
P/S (TTM)	0.10×
P/B	0.13×
PEG	0.00×
P/FCF (TTM)	-0.04×
EV / EBITDA	-1.49×
EV / Sales	-0.41×
Earnings Yield	-1783.75%
Free Cash Flow Yield	-2779.89%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$1.74M
Net Income (TTM)	-$7.73M
Free Cash Flow (TTM)	-$12.10M
Net Debt	-$2.17M
Working Capital	$2.17M
Gross Margin	48.63%
Operating Margin	-299.11%
Net Margin	-294.91%
Return on Equity	-170.36%
Return on Invested Capital	-176.09%